Contact — NextGen Peptides

Get in touch

NextGen Peptides is a small independent desk maintained to keep the incretin-class literature summaries accurate and current. The fastest way to reach us is via email.

What we welcome

Citation corrections. If a specific number, hazard ratio, or study attribution is wrong — tell us, with the source. We will check it against the primary publication and correct or note it.

New publications. The Phase 3 retatrutide trials (TRIUMPH series) and tirzepatide cardiovascular-outcomes data will change the picture materially when they report. If you have a citation we have missed, we want to know.

Structural feedback. If a section is confusing, overstates certainty, or understates a safety signal — that is useful feedback too.

We do not respond to inquiries about sourcing any compound, to requests for medical advice, or to marketing messages.

What we do not handle

This site does not sell products, provide referrals, or give medical or clinical guidance of any kind. Questions about whether a compound is appropriate for a specific person, how to use it, where to obtain it, or how to combine it with other medications are outside the scope of this desk entirely — those questions belong with a qualified healthcare provider.

For research-grade compound sourcing or clinical trial participation questions, consult ClinicalTrials.gov for active trial enrollment.